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Abstract
Ciguatera fish poisoning (ciguatera) is a common clinical syndrome in areas where there is 
dependence on tropical reef fish for food. A subset of patients develops recurrent and, in some 
instances, chronic symptoms, which may result in substantial disability. To identify possible 
biomarkers for recurrent/chronic disease, and to explore correlations with immune gene 
expression, peripheral blood leukocyte gene expression in 10 ciguatera patients (7 recurrent, 3 
acute) from the U.S. Virgin Islands, and 5 unexposed Florida controls were evaluated. Significant 
differences in gene expression were noted when comparing ciguatera patients and controls; 
however, it was not possible to differentiate between patients with acute and recurrent disease, 
possibly due to the small sample sizes involved.
* jgmorris@epi.ufl.edu.
arobertson@disl.org, sroberts@som.umaryland.edu, lgrattan@som.umaryland.edu
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Harmful Algae. Author manuscript; available in PMC 2017 July 01.
Published in final edited form as:














Ciguatera; Gene expression; U.S. virgin islands; Fish poisoning
1. Introduction
Ciguatera fish poisoning (CFP) is caused by consumption of tropical reef fish carrying 
ciguatoxin, a toxin which originates in species of the dinoflagellate Gambierdiscus, and is 
passed up through the marine food chain. Global estimates of incidence are in the range of 
50,000-500,000 cases per year (Fleming et al, 1998). In studies conducted by the research 
team in 2011-2012 on St. Thomas, U.S. Virgin Islands, incidence was 12 cases/1,000 
population/year, with 41% of cases representing recurrent illness (Radke et al, 2013a).
Illness is characterized by a distinctive combination of gastrointestinal (diarrhea, vomiting) 
and neurologic (circumoral and extremity paresthesias, weakness and pain in legs, fatigue) 
symptoms; while gastrointestinal symptoms tend to resolve within 48 hours, neurologic 
symptoms can persist in acute cases for several weeks (Morris et al, 1980; Bagnis et al, 
1979; Radke et al, 2013b). Multiple studies have found that patients who have had ciguatera 
once are significantly more likely to have recurrent episodes (Bagnis et al, 1979; Glaziou & 
Martin, 1993; Morris et al, 1982; Radke et al, 2013a). A subset of patients develop “chronic” 
ciguatera, which is marked by persistence of symptoms, fatigue (reminiscent of chronic 
fatigue syndromes [Pearn, 1997]), and long-term disability.
There are currently no diagnostic tests for ciguatera: diagnosis is based on clinical 
presentation, and confirmatory electromyography, where appropriate. Factors responsible for 
increased rates of recurrence among persons who have had an initial episode of ciguatera are 
not well understood, nor is it understood why a subset of patients go on to have symptoms of 
chronic disease. To look for biomarkers of illness, and explore factors that may contribute to 
clinical presentation, gene expression in peripheral blood leukocytes (PBLs) collected from 
10 patients in the U.S. Virgin Islands who had been diagnosed with CFP and 5 healthy 
control subjects from Florida was assessed..
2. Methods
Ten patients with CFP were drawn from a larger study of acute and recurrent CFP on the 
Island of St. Thomas, U.S. Virgin Islands. As previously described (Radke et al, 2013b), 
patients were enrolled from the Emergency Department of the Roy Lester Schneider 
Hospital (the only hospital on St. Thomas), with follow-ups at 3, 6, and 12 months after 
acute presentation. Seven of the 10 patients had been followed for between 3 and 12 months 
after acute illness, and had recurrent symptoms. Three patients did not have recurrent 
symptoms after their initial illness. For one patient, blood was drawn for the current study 
approximately 4 months from the time of acute illness; the remaining two patients were 
approximately two weeks from the time of their acute episode of illness, and still had 
residual symptoms. The mean age of ciguatera case patients was 55 years; 4 were male and 
6 female. Eight of the 10 patients had an underlying medical diagnosis, including diabetes (2 
patients), arthritis (2), hypertension (4), atherosclerotic heart disease (1), thyroid disease (1), 
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and asthma (1). Samples were also collected from 5 control persons: mean age was 35; 4 
were male and 1 was female; all lived in Florida; all were in good health; and none had any 
medical history consistent with CFP. Studies were approved by the Institutional Review 
Board of the University of Florida.
Whole Blood was collected into a 7.0 mL K3 EDTA vacutainer tube (Becton Dickinson 
#366450). The whole blood was lysed with Buffer EL (Qiagen #79217) to eliminate red 
blood cells and isolate the total leukocyte population. For the CFP patient samples only, 
RNAprotect Cell Reagent (Becton Dickinson #76526) was added to the resultant total 
leukocyte population to stabilize the cells for subsequent shipment to Florida. The total 
leukocytes for the CFP and control patients were then processed with the Qiagen RNeasy 
Plus Mini Kit (Qiagen #74134) to isolate the RNA.
Total RNA was quantified spectrophotometrically using the NanoDrop 1000 instrument 
(Thermo Scientific, Wilmington, DE). RNA quality was assessed using an RNA PicoChip 
on an Agilent 2100 BioAnalyzer (Agilent, Andover, MA). All specimens had RNA Integrity 
Number (RIN) scores greater than 5. 100ng of total RNA was processed for GeneChip 
analysis using the GeneChip® WT PLUS Reagent Kit (Affymetrix, Santa Clara, CA) 
following manufacturer's recommendations. 5.5 coof resulting cDNA was fragmented, 
terminally labeled, and targets were hybridized to Affymetrix GeneChip® Human 
Transcriptome Array 2.0 (HTA 2.0) for 16 h at 45°C and washed according to Affymetrix 
fluidics protocols FS450_001. Microarrays were normalized using Robust Multi-array 
Average (RMA) as implemented in Partek Genomics Suite 6.6 (Partek Incorporated, St 
Louis MO). Only annotated probe sets were used in the subsequent analysis. The resulting 
26,831 annotated probe sets represented 25,193 genes. Significant genes (p<0.001) were 
identified using the class prediction tool implemented in Biometric Research Branch BRB-
ArrayTools version 4.3.0 Stable Release, developed by Richard Simon & BRBArrayTools 
Development Team (http://linus.nci.nih.gov/BRB-ArrayTools.html). The ability of genes 
significant at p<0.001 to distinguish between the classes was determined using leave-one-
out-cross-validation studies and Monte Carlo simulations using algorithms implemented in 
BRB-Array Tools. Gene set analysis was also conducted using BRB ArrayTools.
3. Results and Discussion
Significant differences in PBL gene expression patterns were seen in CFP patients compared 
with controls, with 3285 of 26831 genes screened having a significance of p<0.001. 
Findings are reflected in the principal component analysis shown in Figure 1, and the heat 
map in Figure 2. Significant differences in gene expression were not seen when CFP patients 
with recurrent symptoms were compared with those with only acute symptoms. In assessing 
differences in patterns of expression of genes/gene pathways, the strongest associations were 
with genes linked with platelet aggregation (h_ephA4Pathway) and chemokine gene 
expression (h_fMLPPathway)(Table 1).
The finding of significant differences in PBL gene expression patterns between patients in 
the U.S. Virgin Island ciguatera population and a healthy control population from Florida 
must be approached with caution. It is well recognized that gene expression studies have the 
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potential to yield false positive findings if the ancestry of cases and controls are not 
appropriately matched, as gene expression can be both heritable and under strong genetic 
control (Byrnes et al, 2009; Cheung et al, 2005). In these studies, the majority of the CFP 
patients came either from the Virgin Islands or neighboring islands in the Caribbean; the 
controls, in contrast, tended to have Caucasian backgrounds. To confirm the findings, it will 
be necessary to conduct additional studies, with carefully matched cases and controls. 
Similarly, failure to find significant differences in gene expression between patients with 
recurrent and acute ciguatera is of uncertain relevance: acute case numbers, in particular, 
were small, and blood was drawn, in one instance, 4 months after the initial acute episode.
There are also uncertainties regarding the physiologic relevance of the gene pathways that 
were shown to have significantly different expression patterns. Ciguatoxin, the causative 
agent for the disease, potentiates voltage-gated sodium channels, with resultant effects on 
neurons; there is also a suggestion that it has direct, calcium-mediated enterotoxin activity 
(Fasano et al, 1991). While relevance to human cases is uncertain, there is one study of gene 
expression in mouse brains exposed to ciguatoxin in which there was enrichment of 
expression pathways related to complement and coagulation cascades (Ryan et al, 2010). 
Given the clinical similarities between chronic ciguatera and chronic fatigue syndromes, it 
could be hypothesized that similar physiologic mechanisms were operational in the two 
syndromes. There was some overlap with gene pathways identified in patients with chronic 
fatigue (e.g., ARF1 [Vernon et al, 2002]; CEACAM family [Kaushik et al, 2005]); however, 
more recent studies have raised questions about the relevance of these findings (Byrnes et al, 
2009).
Ciguatera remains an important clinical entity in areas where there is high dependence on 
tropical reef fish for food. Identification of a biomarker for CFP (particularly recurrent or 
chronic CFP), and/or for CFP susceptibility, would have substantial clinical relevance, both 
in terms of diagnosis, and as a basis for development of therapeutic interventions. Findings 
of this preliminary study are intriguing: there is a need to follow-up on these results (with 
appropriate control populations) and to further explore potential physiologic relevance of the 
identified gene pathways.
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A 3D Principal component analysis (PCA) plot of the RNA data that characterizes the trends 
exhibited by the expression profiles of Ciguatera Fish Poisoning (red) and Healthy controls 
(blue). Each dot represents a sample and each color represents the type of the sample.
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Hierarchical clustering of 3285 genes differentially expressed between CFP and Controls at 
a significance of p<0.001 . Each row of the data matrix represents a gene and each column 
represents a sample. Expression levels are depicted according to the color scale shown at the 
bottom. Red and blue indicate expression levels respectively above and below the mean.
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Table 1
Table provides a list of gene sets that pass p< 0.005 threshold among any one of the four tests: Least Square 
(LS) permuation test, The Kolmogorov-Smirnov (KS) permutation test, and Efron-Tibshirani's Gene Set 
Analysis (GSA) maxmean test.









1 h_ephA4Pathway Eph Kinases and ephrins 
support platelet aggregation
8 < 0.005 < 0.005 < 0.005 (−)
2 h_fMLPpathway fMLP induced chemokine gene 
expression in HMC-1 cells
34 < 0.005 < 0.005 < 0.005 (+)
3 h_il7Pathway IL-7 Signal Transduction 15 < 0.005 < 0.005 0.04 (−)
4 h_mapkPathway MAPKinase Signaling Pathway 85 < 0.005 < 0.005 0.04 (+)
5 h_ptdinsPathway Phosphoinositides and their 
downstream targets.
23 < 0.005 < 0.005 < 0.005 (+)
6 h_keratinocytePathway Keratinocyte Differentiation 57 < 0.005 < 0.005 0.085 (+)
7 h_pyk2Pathway Links between Pyk2 and Map 
Kinases
27 < 0.005 < 0.005 0.03 (+)
8 h_bcrPathway BCR Signaling Pathway 33 < 0.005 < 0.005 0.015 (−)
9 h_metPathway Signaling of Hepatocyte 
Growth Factor Receptor
33 < 0.005 < 0.005 0.075 (+)
10 h_tcrPathway T Cell Receptor Signaling 
Pathway
44 < 0.005 < 0.005 0.03 (−)
11 h_monocytePathway Monocyte and its Surface 
Molecules
12 < 0.005 0.009 0.025 (−)
12 h_ucalpainPathway uCalpain and friends in Cell 
spread
14 < 0.005 < 0.005 0.065 (+)
13 h_lymphocytePathway Adhesion Molecules on 
Lymphocyte
10 < 0.005 0.007 0.01 (−)
14 h_tidPathway Chaperones modulate 
interferon Signaling Pathway
29 < 0.005 < 0.005 0.08 (+)
15 h_p53hypoxiaPathway Hypoxia and p53 in the 
Cardiovascular system
24 < 0.005 < 0.005 0.06 (+)
16 h_fcer1Pathway Fc Epsilon Receptor I 
Signaling in Mast Cells
39 < 0.005 < 0.005 0.18 (+)
17 h_integrinPathway Integrin Signaling Pathway 34 < 0.005 < 0.005 0.01 (+)
18 h_HivnefPathway HIV-I Nef: negative effector of 
Fas and TNF
67 < 0.005 < 0.005 0.23 (+)
19 h_neutrophilPathway Neutrophil and Its Surface 
Molecules
9 < 0.005 0.013 0.015 (+)
20 h_il2rbPathway IL-2 Receptor Beta Chain in T 
cell Activation
37 < 0.005 < 0.005 0.135 (+)
21 h_pparaPathway Mechanism of Gene Regulation 
by Peroxisome Proliferators via 
PPARa(alpha)
63 < 0.005 0.022 0.035 (+)
22 h_bArrestin-srcPathway Roles of ¿-arrestin-dependent 
Recruitment of Src Kinases in 
GPCR Signaling
17 < 0.005 0.054 0.015 (+)
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23 h_biopeptidesPathway Bioactive Peptide Induced 
Signaling Pathway
29 < 0.005 0.006 0.04 (+)
24 h_SARSpathway SARS Coronavirus Protease 7 < 0.005 0.022 < 0.005 (−)
25 h_thelperPathway T Helper Cell Surface 
Molecules
12 < 0.005 < 0.005 0.125 (−)
26 h_rac1Pathway Rac 1 cell motility signaling 
pathway
21 < 0.005 < 0.005 0.085 (+)
27 h_hcmvPathway Human Cytomegalovirus and 
Map Kinase Pathways
17 < 0.005 0.025 0.045 (+)
28 h_ecmPathway Erk and PI-3 Kinase Are 
Necessary for Collagen Binding 
in Corneal Epithelia
19 < 0.005 < 0.005 0.145 (−)
29 h_erkPathway Erk1/Erk2 Mapk Signaling 
pathway
27 < 0.005 0.044 0.1 (+)
30 h_no2il 12Pathway NO2-dependent IL 12 Pathway 
in NK cells
15 < 0.005 0.015 0.08 (−)
31 h_dcPathway Dendritic cells in regulating 
TH1 and TH2 Development
17 < 0.005 0.149 0.2 (−)
32 h_nkcellsPathway Ras-Independent pathway in 
NK cell-mediated cytotoxicity
27 < 0.005 0.070 0.2 (−)
33 h_ceramidePathway Ceramide Signaling Pathway 21 < 0.005 0.140 0.05 (+)
34 h_stat3Pathway Stat3 Signaling Pathway 8 < 0.005 < 0.005 0.05 (+)
35 h_chemicalPathway Apoptotic Signaling in 
Response to DNA Damage
18 < 0.005 0.057 0.105 (−)
36 h_rasPathway Ras Signaling Pathway 22 < 0.005 < 0.005 0.015 (+)
37 h_agrPathway Agrin in Postsynaptic 
Differentiation
35 < 0.005 0.087 0.175 (+)
38 h_At1rPathway Angiotensin II mediated 
activation of JNK Pathway via 
Pyk2 dependent signaling
27 < 0.005 0.015 0.045 (+)
39 h_crebPathway Transcription factor CREB 
and its extracellular signals
22 < 0.005 0.006 0.07 (+)
40 h_cxcr4Pathway CXCR4 Signaling Pathway 19 < 0.005 < 0.005 0.055 (+)
41 h_stathminPathway Stathmin and breast cancer 
resistance to antimicrotubule 
agents
20 < 0.005 < 0.005 0.12 (−)
42 h_calcineurinPathway Effects of calcineurin in 
Keratinocyte Differentiation
18 < 0.005 < 0.005 0.06 (−)
43 h_tcytotoxicPathway T Cytotoxic Cell Surface 
Molecules
12 < 0.005 < 0.005 0.135 (−)
44 h_erk5Pathway Role of Erk5 in Neuronal 
Survival
14 < 0.005 < 0.005 0.025 (+)
45 h_fasPathway FAS signaling pathway (CD95 ) 34 < 0.005 0.234 0.225 (−)
46 h_ghPathway Growth Hormone Signaling 
Pathway
27 < 0.005 < 0.005 0.035 (+)
47 h_d4gdiPathway D4-GDI Signaling Pathway 12 < 0.005 0.012 0.21 (−)
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48 h_RacCycDPathway Influence of Ras and Rho 
proteins on G1 to S Transition
26 < 0.005 0.123 0.03 (+)
49 h_ptenPathway PTEN dependent cell cycle 
arrest and apoptosis
18 < 0.005 < 0.005 0.055 (+)
50 h_tcapoptosisPathway HIV Induced T Cell Apoptosis 9 0.008 < 0.005 0.14 (−)
51 h_malPathway Role of MAL in Rho-Mediated 
Activation of SRF
19 0.008 < 0.005 0.01 (+)
52 h_ps1Pathway Presenilin action in Notch and 
Wnt signaling
14 0.009 < 0.005 0.08 (+)
53 h_mef2dPathway Role of MEF2D in T-cell 
Apoptosis
17 0.009 < 0.005 0.01 (−)
54 h_hdacPathway Control of skeletal myogenesis 
by HDAC & calcium/
calmodulin-dependent kinase 
(CaMK)
25 0.017 < 0.005 0.235 (−)
55 h_RELAPathway Acetylation and Deacetylation 
of RelA in The Nucleus
21 0.017 < 0.005 0.125 (+)
56 h_ranbp2Pathway Sumoylation by RanBP2 
Regulates Transcriptional 
Repression
11 0.019 < 0.005 0.07 (−)
57 h_salmonellaPathway How does salmonella hijack a 
cell
5 0.049 < 0.005 0.15 (−)
58 h_pitx2Pathway Multi-step Regulation of 
Transcription by Pitx2
15 0.059 < 0.005 0.14 (+)
59 h_ctla4Pathway The Co-Stimulatory Signal 
During T-cell Activation
30 0.062 < 0.005 0.255 (−)
60 h_classicPathway Classical Complement Pathway 27 0.779 < 0.005 0.515 (+)
61 h_compPathway Complement Pathway 38 0.800 < 0.005 0.465 (+)
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